NVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novo Nordisk is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is facing multiple headwinds, including negative sentiment from analysts, regulatory scrutiny, and weak technical indicators. While the financial performance shows modest growth, the lack of significant positive catalysts and the bearish market sentiment make it prudent to hold off on investing for now.
The technical indicators show a bearish trend. The MACD histogram is negative and contracting, RSI is neutral but leaning towards oversold territory, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 40.895, with key support at 36.35 and resistance at 45.441.
Hedge funds have increased their buying activity by 112.57% over the last quarter. Novo Nordisk also received FDA approval for expanded indications of Sogroya for growth disorders, which could support long-term growth.
The FDA issued a warning regarding misleading claims in Novo Nordisk's Ozempic advertisement, leading to negative sentiment. Analysts have downgraded the stock significantly following disappointing REDEFINE-4 trial results, and there are no near-term catalysts to drive growth. Additionally, Eli Lilly's competitive pricing and Medicare's coverage of obesity drugs could pressure Novo Nordisk's market share.
In Q4 2025, Novo Nordisk reported modest growth with revenue up 0.69% YoY, net income up 3.84% YoY, and EPS up 3.30% YoY. However, gross margin dropped by -4.65% YoY to 80.86, indicating some pressure on profitability.
Analyst sentiment is predominantly negative. Multiple downgrades have occurred recently, with price targets being significantly reduced. The REDEFINE-4 trial results have raised concerns about mid-term growth and competitive pressures.
